

## United States Patent and Trademark Office

COMMISSIONER FOR PATENTS

United States	COMMISSIONER FOR PALENTE PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 2023I WASHINGTON, D.C. 2023I
	ATTORNEY DOCKET NUMBER

ATTORNEY DOCKET NUMBER	UNITED STATES PAIENTS	
FIRST NAMED APPLICANT 2307K-08504003	F	
Israel R. Charo CONFIRMATION NO. 6948		STATED STATES IF BASE
FORMALITIES LETTER	ATION NUMBER 07/25/2000 07/25/3	APPLICA 09

TOWNSEND AND TOWNSEND AND CREW, LLP TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834



Date Mailed: 08/23/2002

SEP 1 7 2002

ENOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated PRADEMA PRADEMA

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where considering includes as some matter of control by 27 CEB 4 924/6 4 924/6 4 924/6 4 924/6 4 924/6 in computer readable form is identical to the whiten (on paper of compact disc) sequence issuing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(f), 1.821(g), 1.825(b), or where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(f), 1.821(g), 1.825(b), or where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(f), 1.821(g), 1.825(b), or where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(f), 1.821(f), 1.821(f), 1.825(b), or where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821 where applicable, includes no new maller, as required by 37 CFR 1.021(8), 1.021(9), 1. 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1228 OC 145 (September 10, 2000)
  - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 A copy of the Sequence Listing in computer readable form has not been submitted as required by 57 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, and 1229 Oc. 145 (Contember 8). Dublished in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000) Applications of the research of the federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000) Applications of the research of the federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000) Applications of the research of the resear published in the rederal Register at 00 FR 34004 (September 0, 2000) and 1230 US 143 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and 1230 US 143 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and 1230 US 143 (September 0, 2000). a statement that the content of the sequence listing information recorded in computer readable form is a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new identical to the written (on paper or compact disc) 4 924(a) 4 924(b) 6 identical to the written (on paper or compact disc) sequence using and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with that of another confidence in the instant application to be identical with the confidence in the instant application to be identical with the confidence in the instant application to be identical with the confidence in the instant application to be identical with the confidence in the instant application to be identical with the confidence in the instant application to be identical with the confidence in the instant application to be identical with the confidence in the instant application application and the instant application applicat sequence listing in the instant application to be identical with that of another application on file in the U.S. Sequence issuing in the instant application to be identical with that of another application on tile in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu

For questions regarding compliance to these requirements, please contact: of a new CRF.

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice  $\underline{MUST}$  be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY